10-K: Milestone Scientific Reports 2024 Results, Navigates Financial Challenges

Milestone Scientific's 2024 10-K filing reveals a decrease in revenue, continued operating losses, and efforts to secure additional funding while expanding its medical product line and distribution.

Summary

• Milestone Scientific reported a net loss of $4.7 million for 2024, compared to a $6.9 million loss in 2023.
• Revenue decreased to $8.6 million in 2024 from $9.8 million in 2023, with dental sales declining and medical sales increasing slightly.
• The company is focusing on its E-Commerce platform, which accounted for $5.1 million in revenue in 2024, compared to $4.8 million in 2023.
• International revenue decreased by $756,000, with no revenue from China in 2024 compared to $270,000 in 2023.
• Operating expenses decreased by approximately $840,000 due to lower employee salaries and benefits, warehousing, marketing, and travel expenses.
• Research and development expenses increased by $157,000 due to the development of the next generation STA Single Tooth Anesthesia System.
• The company is pursuing additional funding through public or private equity offerings, collaborations, and licensing arrangements.
• Milestone Scientific received regulatory approval in Brazil for its CompuFlo Epidural System and favorable Medicare Part B physician price assignments in Florida, Delaware, District of Columbia, Maryland, New Jersey, Pennsylvania, Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
• The company has a strategic partnership with Axial Biologics to distribute the CompuFlo Epidural System in New Jersey, Texas, and Florida.
• Milestone Scientific holds approximately 317 U.S. and foreign patents and relies on third-party manufacturers for its products.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in reducing its net loss and expanding its medical product line and distribution, it faces significant financial challenges, including declining revenue and the need for additional funding. The auditor's concern about the company's ability to continue as a going concern adds to the negative sentiment.

Positives

• The net loss decreased from $6.9 million in 2023 to $4.7 million in 2024.
• E-Commerce revenue increased to $5.1 million in 2024 from $4.8 million in 2023.
• Operating expenses decreased by approximately $840,000.
• Research and development expenses increased by $157,000.
• The company received regulatory approval in Brazil for its CompuFlo Epidural System.
• The company has a strategic partnership with Axial Biologics to distribute the CompuFlo Epidural System in New Jersey, Texas, and Florida.
• The company received favorable Medicare Part B physician price assignments in Florida, Delaware, District of Columbia, Maryland, New Jersey, Pennsylvania, Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

Negatives

• Revenue decreased to $8.6 million in 2024 from $9.8 million in 2023.
• International revenue decreased by $756,000, with no revenue from China in 2024 compared to $270,000 in 2023.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.

Risks

• The company has incurred significant losses since its inception and expects these operating losses to continue.
• The company may be unable to raise capital when needed, which may force it to delay, curtail, or eliminate parts of its operations.
• The company relies exclusively on third parties to manufacture its products, and changes in these arrangements or disruptions at the manufacturing facilities could harm its business.
• Developments by competitors may render the company's products or technologies obsolete or non-competitive.
• The company is exposed to risks inherent in international sales, including fluctuations in foreign currency exchange rates and unexpected changes in political or regulatory environments.
• The company's business is exposed to risks associated with the economic, environmental, and political conditions in China because the sole manufacturer of its handpieces is in China.
• The company is subject to substantial domestic and international government regulation, and failure to comply with these standards could have an adverse effect on its business.
• Changes to trade policy, including tariff and import/export regulations, may have a material adverse effect on the company's results of operations, cash flows, and financial condition.

Future Outlook

Milestone Scientific is focused on increasing revenue from its dental and medical businesses, reducing operating expenses, and pursuing additional funding to support its operations.

Industry Context

The medical device industry is intensely competitive and subject to rapid and significant technological change. Milestone Scientific competes with other companies in the development of alternative injection-based or imaging-based systems.

Comparison to Industry Standards

• The document mentions competitors such as Quicksleeper, SleeperOne, Dentapen, Anaeject, Calajet, Comfort Control Syringe, EpiFaith Syringe, and Epidrum.
• It states that Milestone Scientific's devices compete based on their performance characteristics and the benefits provided to the patient, practitioner, and their business operations.
• The document claims that Milestone Scientific, Inc. continues to be the leader in this category based on the sheer number of scientific studies performed with its technologies.

Management Changes

Related Party Transactions

• Milestone Scientific has a supply agreement with United Systems, the principal supplier of its handpieces.
• The Director of Clinical Affairs receives royalty and consulting fees from Milestone Scientific.
• Leonard Osser receives compensation under an Employment Agreement and a Consulting Agreement.
• The University Pain Medicine Center (STEMMEE), of which Dr. D. Demesmin is the CEO, purchases products from Milestone Scientific.
• The Company entered into a consulting agreement with Mr. Arjan Haverhals.
• On April 9, 2025, the Company issued a series of promissory notes in the aggregate amount of $800,000, to Mr. Neal Goldman, Ms. Benedetta Casamento, and Dr. Didier Demesmin, each of whom is a director of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital by issuing equity securities.
• Employees may be affected by potential delays, curtailments, or eliminations of research and development programs or other operations if the company is unable to raise capital.
• Customers may be affected by potential disruptions in the supply of products if the company's manufacturing relationships are terminated or interrupted.
• Suppliers may be affected by potential changes in the company's purchasing patterns if the company's financial condition deteriorates.

Next Steps

• The company is focused on increasing revenue from its dental and medical businesses.
• The company is focused on reducing operating expenses.
• The company is pursuing additional funding to support its operations.

Key Dates

Keywords

Milestone Scientific, financial results, revenue, net loss, E-Commerce, CompuFlo Epidural System, STA Single Tooth Anesthesia System, patents, regulatory approval, distribution, manufacturing, risk factors, going concern, Medicare, Medicaid